Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label long-term safety study of DCCR in Prader-Willi syndrome
2025-000181-28Phase 3
- Sponsor
- Soleno Therapeutics
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of diazoxide in Prader-Willi syndrome (PWS), sponsored by Soleno Therapeutics. Primary endpoints: Adverse event reports, Clinical laboratory assessments and 1 more.
02
Drugs
diazoxide
03
Conditions
Prader-Willi syndrome (PWS)
Beyond the preview
Go deeper on 2025-000181-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-000181-28.